Clinical trials · Massachusetts
Cancer clinical trials in Massachusetts
We’re tracking 758 recruiting cancer studies with a site in Massachusetts — including Phase 1, Phase 1/Phase 2, Phase 2, Phase 2/Phase 3 and Phase 3 studies, each written for real people, not researchers.
Recruiting studies in Massachusetts
- NCT06945120Recruiting
Lung Health Program for Chinese and Korean Smokers
This study is testing a program to help Chinese and Korean adults who smoke to improve their lung health. You may be able to join if you are a current smoker, speak Korean, Mandarin, or English, and live in the U.S.
Boston, MassachusettsAges 18–100 - NCT06923397Recruiting
Stopping long sitting time during lymphoma chemo (iSTAND Trial)
This study looks at whether taking short, frequent breaks from sitting can help people with lymphoma who are starting chemotherapy feel better and have fewer side effects. If you join, you'll get a wearable activity tracker and text reminders to stand up and move gently throughout your day.
Boston, MassachusettsAges 18 years+ - NCT06923527RecruitingPhase 2
Testing ctDNA to start elacestrant in early breast cancer
This trial tests whether the drug elacestrant can help prevent recurrence in people with a type of breast cancer (ER+/HER2-) who have finished hormone therapy and have signs of cancer DNA in their blood (ctDNA positive) but no visible spread on scans.
Boston, MassachusettsAges 18 years+ - NCT06926868RecruitingPhase 2/Phase 3
Study of a new drug versus chemotherapy for advanced triple-negative breast cancer
This trial tests a new investigational drug called izalontamab brengitecan against standard chemotherapy for people with advanced triple-negative breast cancer who cannot receive immunotherapy. The goal is to see if the new drug works better at shrinking or slowing the cancer.
Boston, MassachusettsAges 18 years+ - NCT06917911RecruitingPhase 2
Testing two drug additions to standard chemotherapy for a type of acute myeloid leukemia
This trial tests whether adding venetoclax or gemtuzumab ozogamicin to the usual chemotherapy helps people with a specific genetic type of acute myeloid leukemia (AML) respond better. It may improve chances of remission.
Boston, MassachusettsAges 18–59 - NCT06919965RecruitingPhase 3
TAR-210 vs. standard bladder chemo for high-risk bladder cancer
This trial compares a new drug called TAR-210, given directly into the bladder, to standard chemotherapy for people with a specific type of high-risk bladder cancer that has not invaded muscle. It tests if TAR-210 can be more effective with fewer side effects.
Plymouth, MassachusettsAges 18 years+ - NCT06908928RecruitingPhase 1
Study of Bulumtatug Fuvedotin for advanced triple-negative breast cancer
This study tests a new drug called bulumtatug fuvedotin for people with triple-negative breast cancer that has spread or come back. It's for those who have already tried certain other treatments, including a taxane and a specific type of antibody-drug conjugate.
Boston, MassachusettsAges 18 years+ - NCT06907797Recruiting
Beta test of equity app for acute leukemia patients
This study is beta-testing a new app designed to reduce healthcare disparities among people admitted to the hospital with suspected acute leukemia. Your feedback could help make the app more helpful for future patients.
Boston, MassachusettsAges 18 years+ - NCT06890598RecruitingPhase 3
Study of olomorasib for KRAS G12C-mutant lung cancer
This trial tests a new targeted therapy (olomorasib) combined with standard treatments for people with a specific type of non-small cell lung cancer that has a KRAS G12C mutation. Depending on the stage of your cancer, you may receive it before or after surgery, or along with chemotherapy and radiation.
Burlington, MassachusettsAges 18 years+ - NCT06875310RecruitingPhase 3
Study of adagrasib plus pembrolizumab plus chemotherapy for KRAS G12C lung cancer
This trial tests if adding the targeted drug adagrasib to standard immunotherapy and chemotherapy helps people with a specific KRAS G12C mutation in non-squamous non-small cell lung cancer that has spread. It is for people who have not had previous treatment for advanced disease.
Boston, MassachusettsAges 18 years+ - NCT06862856Recruiting
PET Scan for Men With Very Low PSA After Prostate Surgery
This trial tests a PET scan (flotufolastat F 18) to find tiny prostate cancer cells in men whose PSA is very low but still rising after prostate removal. It may help guide further treatment decisions.
Boston, MassachusettsAges 18 years+ - NCT06850623RecruitingPhase 2
Sound wave therapy plus chemo for advanced pancreatic cancer
This trial tests a new treatment that uses sound waves to help chemotherapy reach pancreatic tumors more effectively. It is for people with locally advanced pancreatic cancer that cannot be removed with surgery.
Boston, MassachusettsAges 18 years+ - NCT06855771RecruitingPhase 2
Study of navlimetostat alone or with izalontamab for advanced lung cancer
This trial tests a new drug, navlimetostat, either by itself or combined with another drug, izalontamab, for people with advanced non-small cell lung cancer that has a specific genetic change (MTAP loss). The goal is to see if these treatments can help shrink tumors or slow cancer growth.
Boston, MassachusettsAges 18 years+ - NCT06831552Recruiting
Supporting families of children with high-risk neuroblastoma
This study tests a resource intervention to help families with low income who have a child with high-risk neuroblastoma. It aims to reduce financial stress and improve care during treatment.
Boston, MassachusettsAges Up to 17 years - NCT06807086Recruiting
Online talk therapy for insomnia in cancer survivors
This study tests if online therapy sessions can help cancer survivors with long-term sleep problems (insomnia). It is for people who have finished or are still in active cancer treatment, including those with stable metastatic cancer.
Boston, MassachusettsAges Any age - NCT06786104Recruiting
Video talks about ethical choices for kids with cancer
This trial uses videos to help parents and doctors discuss tough ethical decisions for children with cancer. It aims to guide conversations about treatment goals and care options.
Boston, MassachusettsAges Any age - NCT06780670RecruitingPhase 2/Phase 3
Comparing a new treatment to standard care for advanced prostate cancer
This study tests a new drug (AAA817) against the usual treatments for men with advanced prostate cancer that has stopped responding to a type of targeted radiation therapy (Lu-PSMA). The goal is to see if the new drug can slow the cancer's growth better than standard options.
Boston, MassachusettsAges 18–100 - NCT06773195RecruitingPhase 1/Phase 2
Study of Ruxolitinib and Ulixertinib for Myelofibrosis
This trial tests a new combination of two drugs, ruxolitinib and ulixertinib, for people with myelofibrosis whose disease is not fully controlled by ruxolitinib alone. The goal is to see if adding ulixertinib can improve spleen enlargement, symptoms, or bone marrow changes.
Boston, MassachusettsAges 18 years+ - NCT06765109RecruitingPhase 3
Testing neladalkib for untreated ALK-positive lung cancer
This study tests a new pill called neladalkib to see if it works better than the current standard treatment (alectinib) for people with ALK-positive lung cancer who have not yet received any cancer therapy for advanced disease. It may be a good option if you have ALK-positive NSCLC and have not been treated before.
Boston, MassachusettsAges 18 years+ - NCT06767514RecruitingPhase 3
Ivonescimab for first-line treatment of advanced NSCLC with high PD-L1
This trial tests a new drug called Ivonescimab as the first treatment for people with advanced (stage IV) non-small cell lung cancer whose tumors have high levels of PD-L1 (a protein that helps cancer hide from the immune system). The goal is to see if it can help shrink or control the cancer.
Boston, MassachusettsAges 18 years+ - NCT06763432Recruiting
Colonoscopy readiness study
This study helps patients aged 45–75 at Codman Square Health Center get ready for a colonoscopy to screen for colon cancer. It aims to make the process easier and more comfortable.
Boston, MassachusettsAges 45–75 - NCT06757192Recruiting
Colorectal cancer screening study for adults 45-54
This study is looking for people aged 45 to 54 who have not been screened for colorectal cancer (CRC) yet. It aims to understand and improve screening rates. You may be eligible if you are a patient at the health center and have no personal or family history of colorectal cancer.
Boston, MassachusettsAges 45–54 - NCT06759649RecruitingPhase 1
Study of COM503 for advanced solid tumors
This trial tests a new drug called COM503 for people with advanced solid tumors that have not responded to or cannot be treated with standard therapies. It aims to see if the drug is safe and how well it works.
Boston, MassachusettsAges 18 years+ - NCT06747845RecruitingPhase 2
Maintenance therapy for stable metastatic pancreatic cancer
This trial tests a combination of two drugs, niraparib and ipilimumab, as a maintenance treatment for people with metastatic pancreatic cancer that has not grown after initial chemotherapy. The goal is to see if this can help keep the cancer stable longer.
Boston, MassachusettsAges 18 years+
Cancer trials by city in Massachusetts
Where these studies are running in Massachusetts
Institutions with a site for the recruiting cancer studies listed above.
- Dana-Farber Cancer Institute · 14 studies
- Massachusetts General Hospital · 4 studies
- Beth Israel Deaconess Medical Center · 2 studies
- Codman Square Health Center · 2 studies
- Beth Israel Deaconess Medical Center - Division of Hematology/Oncology
- Clinical Study Site
- Greater Boston Urology
- Lahey Hospital and Medical Center
What taking part in a cancer study involves
A screening visit first
Before anything else, the study team checks whether you fit — usually a visit with some tests. You can stop at any point, and screening is typically free.
Care at a nearby site
Study visits happen at a clinic or hospital taking part. Many studies cover the cost of the study treatment and related visits, and some reimburse travel.
You stay in control
Taking part is voluntary and you can leave a study at any time, for any reason, without affecting your regular care.
The team decides eligibility
Our fit check is a helpful first read, not a decision. The study team makes the final call after reviewing your health history.
Cancer trials in other states
Common questions
- Are there cancer clinical trials in Massachusetts?
- Yes. We're currently tracking 758 recruiting cancer studies with a site in Massachusetts, each rewritten in plain language so you can see what it's testing and who it's for.
- How do I find out if I qualify for a cancer study in Massachusetts?
- Each study lists its eligibility rules — age, diagnosis, prior treatments. On every trial page we explain these in plain language and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Do I have to live in Massachusetts to take part?
- Not necessarily. These studies have a site in Massachusetts, but eligibility is about your health, not your address — some people travel to take part, and a few studies reimburse travel. The study team can tell you what's required.
- Does it cost anything to join a cancer trial?
- Using Clin2 is always free. Many trials cover the study treatment and related visits; some reimburse travel. The study team explains exactly what's covered before you decide.
Not the right time?
New cancer studies open in Massachusetts regularly. Set up a health profile and we’ll quietly watch for studies that fit you and email you when one opens.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.